Found: 16
Select item for more details and to access through your institution.
Pterostilbene Induces Cell Apoptosis and Cell Cycle Arrest in T-Cell Leukemia/Lymphoma by Suppressing the ERK1/2 Pathway.
- Published in:
- BioMed Research International, 2017, v. 2017, p. 1, doi. 10.1155/2017/9872073
- By:
- Publication type:
- Article
EZH2 inhibition induces senescence via ERK1/2 signaling pathway in multiple myeloma.
- Published in:
- Acta Biochimica et Biophysica Sinica, 2024, v. 56, n. 7, p. 1055, doi. 10.3724/abbs.2024077
- By:
- Publication type:
- Article
Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation.
- Published in:
- Acta Biochimica et Biophysica Sinica, 2023, v. 55, n. 12, p. 1884, doi. 10.3724/abbs.2023260
- By:
- Publication type:
- Article
A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway.
- Published in:
- Acta Biochimica et Biophysica Sinica, 2023, v. 55, n. 2, p. 215, doi. 10.3724/abbs.2023014
- By:
- Publication type:
- Article
Novel cyclophosphamide of natural products osalmide and pterostilbene induces cytotoxicity and cell cycle arrest in diffuse large B-cell lymphoma cells.
- Published in:
- Acta Biochimica et Biophysica Sinica, 2020, v. 52, n. 4, p. 401, doi. 10.1093/abbs/gmaa009
- By:
- Publication type:
- Article
Targeting the PI3K/Akt/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression.
- Published in:
- Acta Biochimica et Biophysica Sinica, 2018, v. 50, n. 8, p. 782, doi. 10.1093/abbs/gmy070
- By:
- Publication type:
- Article
DCZ3301, a novel aryl-guanidino inhibitor, induces cell apoptosis and cell cycle arrest via suppressing the PI3K/AKT pathway in T-cell leukemia/lymphoma.
- Published in:
- Acta Biochimica et Biophysica Sinica, 2018, v. 50, n. 7, p. 643, doi. 10.1093/abbs/gmy047
- By:
- Publication type:
- Article
PKC inhibition of sotrastaurin has antitumor activity in diffuse large B-cell lymphoma via regulating the expression of MCT-1.
- Published in:
- Acta Biochimica et Biophysica Sinica, 2018, v. 50, n. 4, p. 399, doi. 10.1093/abbs/gmy021
- By:
- Publication type:
- Article
TI17, a novel compound, exerts anti‐MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damage.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 23, p. 21321, doi. 10.1002/cam4.6706
- By:
- Publication type:
- Article
The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13–MAPK–YWHAE signaling pathway.
- Published in:
- Journal of Translational Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12967-023-04739-7
- By:
- Publication type:
- Article
Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2.
- Published in:
- International Journal of Oncology, 2018, v. 53, n. 2, p. 823, doi. 10.3892/ijo.2018.4438
- By:
- Publication type:
- Article
Identification of a novel cuproptosis‐related gene signature for multiple myeloma diagnosis.
- Published in:
- Immunity, Inflammation & Disease, 2023, v. 11, n. 11, p. 1, doi. 10.1002/iid3.1058
- By:
- Publication type:
- Article
Correction to: Obesity-associated up-regulation of lipocalin 2 protects gastric mucosa cells from apoptotic cell death by reducing endoplasmic reticulum stress.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Obesity-associated up-regulation of lipocalin 2 protects gastric mucosa cells from apoptotic cell death by reducing endoplasmic reticulum stress.
- Published in:
- Cell Death & Disease, 2021, v. 12, n. 2, p. 1, doi. 10.1038/s41419-021-03512-2
- By:
- Publication type:
- Article
DCZ0814 induces apoptosis and G0/G1 phase cell cycle arrest in myeloma by dual inhibition of mTORC1/2.
- Published in:
- Cancer Management & Research, 2019, v. 11, p. 4797, doi. 10.2147/CMAR.S194202
- By:
- Publication type:
- Article
The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.
- Published in:
- Oncology Reports, 2017, v. 38, n. 1, p. 488, doi. 10.3892/or.2017.5675
- By:
- Publication type:
- Article